Lido Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Lido Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,846	Closed	-$339K	–	1045
2021 Q2	$339K	Buy	1,846 +70	+4%	+$12K	﹤0.01%	672
2021 Q1	$272K	Buy	1,776 +137	+8%	+$21.2K	﹤0.01%	696
2020 Q4	$256K	Buy	+1,639	New	+$211K	0.01%	680
2020 Q1	–	Sell	-4,768	Closed	-$516K	–	702
2019 Q4	$516K	Sell	4,768 -43	-0.9%	-$4.6K	0.02%	383
2019 Q3	$471K	Buy	4,811 +2,659	+124%	+$300K	0.02%	345
2019 Q2	$281K	Buy	2,152 +22	+1%	+$2.83K	0.02%	437
2019 Q1	$287K	Buy	+2,130	New	+$265K	0.02%	403

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Lido Advisors's ALXN Position: Q3 2021 in Review

Lido Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,846 shares — an estimated $339K sold.

Lido Advisors first reported a position in ALXN in Q1 2019 and held it in 7 quarters. The position peaked at $516K in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Lido Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Lido Advisors sold 1,846 Alexion Pharmaceuticals shares in Q3 2021, an estimated $339K.
Lido Advisors first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 7 quarters.
Lido Advisors's Alexion Pharmaceuticals position peaked at $516K in Q4 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Lido Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.